Gabbard says declassified biolab records validate concerns previously dismissed as misinformation

Gabbard Claims Declassified Files Support Warnings About U.S.-Funded Biological Labs

Gabbard says declassified biolab records validate - Tulsi Gabbard, the Director of National Intelligence, has unveiled a collection of newly declassified documents that shed light on the U.S. financial support for over 120 biological laboratories across more than 30 countries. These records, she argues, confirm fears that were initially dismissed as conspiracy theories or misinformation. The release marks a significant moment in the ongoing discourse about the role of American-funded research facilities in global biosecurity efforts.

A Shift in Narrative

Years after Gabbard faced scrutiny for her early warnings about U.S.-backed laboratories in Ukraine following Russia’s 2022 invasion, the recent declassification of internal documents has reignited discussions about the scope of American biological research programs abroad. At the time, critics accused her of aligning with Russian narratives, suggesting her concerns were politically motivated. Supporters, however, defended her, insisting that legitimate doubts about the labs’ activities and oversight were being unjustly ignored.

The latest documents include briefing slides from the Office of the Director of National Intelligence (ODNI) that outline the U.S. government’s engagement with Ukraine’s laboratory network. Among the findings is the revelation that over 40 Ukrainian labs received U.S. funding and housed collections of pathogens, some dating back to the Soviet era. These labs were involved in studying and storing diseases such as anthrax, tuberculosis, plague, Ebola virus, Marburg virus, MERS, and SARS. The records also detail how Ukrainian scientists participated in training programs sponsored by U.S. agencies, learning to handle hazardous pathogens in high-security environments.

Additional files provide insight into the physical infrastructure of these laboratories. They reveal that U.S. taxpayer funds were used for the construction and modernization of facilities in locations like Kherson, Odesa, and western Ukraine. A key contractor in these projects was the engineering firm Black & Veatch, which was responsible for developing and upgrading the labs. The documents indicate that individual projects cost between $1.7 million and $3.5 million, highlighting the scale of financial commitment to these initiatives.

Focus on Kharkiv’s Lab

One declassified report specifically highlights a veterinary research laboratory in Kharkiv, which received Pentagon funding through the Defense Department’s Biological Threat Reduction Program. According to the document, the facility maintained hundreds of samples of dangerous pathogens, including Brucella bacteria, a pathogen linked to brucellosis. The assessment warns that such labs could become targets for Russian propaganda or be compromised during the war, raising questions about their strategic importance.

The ODNI slides also describe a "web of connections" that ties Ukrainian laboratories to various U.S. entities, including government agencies, academic institutions, and private contractors. This network, the documents suggest, facilitated research on highly infectious diseases like bird flu and other viral threats. Gabbard emphasized that these findings show the public was not fully informed about the extent of American involvement in biological research programs, particularly those operating in conflict zones.

"The documents demonstrate that the public was not given a full picture of U.S.-backed biological research programs overseas," Gabbard stated. "This transparency now allows us to reassess the credibility of earlier claims and the intentions behind these facilities."

Critics remain divided on the implications of the funding. While some argue that the labs were essential for securing pathogens and preventing their spread, others suspect they were used for more sinister purposes, such as biological warfare. The declassification of these records is expected to intensify debates about government transparency, the role of gain-of-function research, and the potential dual-use of scientific advancements.

Public Health vs. Biological Weapons

Supporters of the program insist that the laboratories were part of long-standing efforts to enhance public health infrastructure and reduce the risk of biological threats. They point to the collaboration between U.S. agencies and Ukrainian researchers as a way to strengthen disease surveillance and containment systems. However, opponents highlight the presence of pathogens with high potential for weaponization, such as those capable of causing severe respiratory illnesses or widespread epidemics.

The records also raise questions about the accountability of private contractors involved in these projects. Black & Veatch, for instance, was a major player in the development of several Ukrainian labs. While the firm’s role was focused on engineering and construction, the documents suggest it played a part in enabling the labs’ operations. This has led to calls for further scrutiny of how taxpayer money is allocated to such initiatives and whether private firms are held to the same standards as government agencies.

Experts are now analyzing the declassified materials to determine their relevance to current geopolitical tensions. Some see the files as evidence of a broader strategy to support scientific research in regions of strategic interest, while others fear they could be used to justify covert operations. The release of these documents has also prompted lawmakers to demand more detailed explanations about the U.S. government’s involvement in biological research programs and their potential impact on global security.

Broader Implications

As the debate continues, the declassified records are likely to influence public perception of U.S. biodefense policies. The documents underscore the complexity of these programs, which blend public health goals with military preparedness. With the war in Ukraine still ongoing, the role of these labs in both scientific and strategic contexts remains a focal point for scrutiny.

The new information has the potential to reshape discussions about how biological research is funded and managed. By revealing the extent of U.S. involvement in multiple countries, the records challenge the notion that these labs were purely defensive. Instead, they suggest a multifaceted approach that includes securing pathogens, studying their potential uses, and preparing for their deployment in crisis situations.

As the details of the funding and lab operations become more widely known, the conversation will likely expand beyond Ukraine to include other regions where U.S.-funded biolabs are active. This could lead to a reevaluation of the entire network and its alignment with national security interests. Whether these facilities are seen as critical to global health or as a tool for biological warfare will depend on how the evidence is interpreted and presented in the coming weeks.

In the end, the declassification of these files represents a pivotal step in understanding the U.S. government’s biological research initiatives. While Gabbard’s arguments gain traction, the debate over their true purpose and impact will require further analysis, public engagement, and policy adjustments to address growing concerns about transparency and oversight.